ARQT
MaterialsArcutis Biotherapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving ARQT Today?
No stock-specific AI insight has been generated for ARQT yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
ARQT News
20 articles- Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE ExpansionYahoo Finance·May 9, 2026
- Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Yahoo Finance·May 8, 2026
- Arcutis Biotherapeutics, Inc. Q1 2026 Earnings Call SummaryMoby·May 7, 2026
- Arcutis Biotherapeutics Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Arcutis Announces First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 ReleaseYahoo Finance·Apr 30, 2026
- Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should KnowYahoo Finance·Apr 29, 2026
- Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 MonthsYahoo Finance·Apr 27, 2026
- A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price MovesYahoo Finance·Apr 24, 2026
- How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 TargetYahoo Finance·Apr 23, 2026
- Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis GuidelinesYahoo Finance·Apr 22, 2026
- Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in InfantsYahoo Finance·Apr 19, 2026
- Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026GlobeNewswire Inc.·Apr 15, 2026
- Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow PositiveMarketbeat·Apr 15, 2026
- Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge?Yahoo Finance·Apr 8, 2026
- Arcutis Stock Up 65% as Director Sells 10,000 Shares Under 10b5-1 Plan. Here's What Investors Should KnowThe Motley Fool·Apr 8, 2026
- How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 TargetsYahoo Finance·Apr 8, 2026
- Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of SalesYahoo Finance·Apr 7, 2026
- Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Mar 31, 2026
All 20 articles loaded
Price Data
Fundamentals
Trading
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.